Myeloid cells, such as CD103+ DCs and CD169+ subcapsular macrophages, prime CD8+ T cells in tumor-draining lymph nodes (LNs) by presenting processed tumorigenic peptides, a critical initial step for generating an anti-tumoral immune response (10–12). This evidence concerns the gene CD8A and neoplasm.